P00071267A04
In_II addition_NN ,_, liver_NN biopsy_NN specimens_NNS from_II carriers_NNS with_II anti-HBe_NN were_VBD negative_JJ for_II HbcAg_NN by_II immunofluorescence_NN ,_, and_CC the_DD liver_NN histology_NN was_VBD either_CC normal_JJ or_CC revealed_VVD only_RR fatty_JJ changes_NNS ._.
P00212821A06
The_DD results_NNS indicate_VVB that_CST hepatitis_NN A_NN virus_NN is_VBZ of_II little_DD importance_NN in_II the_DD pathogenesis_NN of_II CAH_NN and_CC confirm_VVB the_DD association_NN between_II hepatitis_NN B_NN virus_NN and_CC development_NN of_II chronic_JJ active_JJ hepatitis_NN ._.
P01517947A08
Ten_MC were_VBD HBeAg_NN and_CC 19_MC anti-HBe_NN seropositive_JJ ._.
P01583107A02
New_JJ IMx_NN assays_NNS for_II HBsAg_NN and_CC immunoglobulin_NN M_NN (_( IgM_NN )_) anti-HBc_NN detection_NN were_VBD also_RR used_VVN ._.
P01663719A05
The_DD stratification_NN analysis_NN of_II interactive_JJ effects_NNS of_II HBV_NN infection_NN markers_NNS on_II the_DD development_NN of_II PHC_NN showed_VVD that_CST HBeAg_NN carrier_NN status_NN may_VM increase_VVB PHC_NN risk_NN associated_VVN with_II HBsAg_NN status_NN ._.
P02104740A08
These_DD findings_NNS suggest_VVB that_CST chronic_JJ hepatitis_NN associated_VVN with_II isolated_VVNJ anti-HBc_NN is_VBZ a_DD heterogenous_JJ pathologic_JJ entity_NN ._.
P02196336A07
Of_II specimens_NNS positive_JJ for_II anti-HBc_NN by_II EIA_NN ,_, 14.8_MC %_SYM were_VBD negative_JJ by_II RIA_NN ._.
P02227250A04
Antibody_NN to_II pre-S2_NN antigen_NN (_( anti-pre-S2_NN )_) was_VBD detected_VVN in_II 16_MC (_( 9.6_MC %_SYM )_) of_II 166_MC subjects_NNS with_II concurrent_JJ markers_NNS ,_, 15_MC of_II these_DD 16_MC carriers_NNS were_VBD positive_JJ for_II antibody_NN to_II HBeAg_NN (_( anti-HBe_NN )_) ._.
P02303802A11
The_DD levels_NNS of_II anti-HBe_NN IgG1_NN and_CC IgG3_NN were_VBD much_RR lower_JJR than_CSN the_DD levels_NNS of_II anti-HBc_NN IgG1_NN and_CC IgG3_NN ._.
P02304145A03
HBV_NN mutants_NNS with_II pre-C-region_NN defects_NNS prevailed_VVD in_II the_DD circulation_NN of_II three_MC asymptomatic_JJ carriers_NNS as_CS they_PN seroconverted_VVD from_II HBeAg_NN to_II the_DD corresponding_VVGJ antibody_NN (_( anti-HBe_NN )_) ,_, and_CC these_DD mutants_NNS finally_RR replaced_VVNJ nondefective_JJ HBV_NN ._.
P02307337A08
We_PN discussed_VVD the_DD presence_NN of_II IgM_NN anti-HBc_NN in_II association_NN with_II HBeAg_NN or_CC liver_NN damage_NN ._.
P02352457A03
HBeAg_NN /_SYM Anti-HBe_NN immune_JJ complexes_NNS were_VBD detected_VVN in_II 17_MC /_SYM 18_MC (_( 94.4_MC %_SYM )_) patients_NNS positive_JJ for_II HBV-DNA_NN ._.
P02411829A03
Antibody_NN to_II hepatitis_NN B_NN e_NN antigen_NN (_( anti-HBe_NN )_) was_VBD present_JJ in_II the_DD serum_NN of_II 93.5_MC %_SYM of_II these_DD carriers_NNS ._.
P02417111A07
To_TO define_VVI the_DD significance_NN of_II these_DD molecular_JJ forms_NNS in_II HB-VP_NN morphogenesis_NN ,_, we_PN studied_VVD the_DD effects_NNS of_II a_DD mild_JJ treatment_NN with_II a_DD chaotropic_JJ salt_NN ,_, NaSCN_NN ,_, on_II HB-VP-rich_JJ fractions_NNS (_( DNA_NN polymerase_NN positive_JJ )_) ._.
P02469730A06
T_NN cell_NN subset_NN fractionation_NN revealed_VVD that_CST CD4+_NN cells_NNS were_VBD main_JJ population_NN of_II IFN-gamma_NN production_NN specific_JJ for_II HBcAg_NN and_CC CD8+_NN cells_NNS did_VDD not_RR suppress_VVB IFN-gamma_NN production_NN of_II CD4+_NN cells_NNS ._.
P02540692A01
Sera_NNS from_II 60_MC consecutive_JJ patients_NNS with_II hepatocellular_JJ carcinoma_NN (_( HCC_NN )_) diagnosed_VVN by_II either_CC a_DD positive_JJ histology_NN or_CC at_RR+ least_RR two_MC of_II the_DD following_VVGN :_: CT_NN scan_NN ,_, hepatic_JJ ultrasound_NN ,_, hepatic_JJ angiogram_NN and_CC raised_VVNJ alpha-foetoprotein_NN levels_NNS ,_, were_VBD studied_VVN to_TO determine_VVI their_PNG Hepatitis_NN B_NN surface_NN antigen_NN (_( HBsAg_NN )_) status_NN and_CC the_DD frequency_NN of_II continuing_VVGJ viral_JJ replication_NN ._.
P02584955A04
In_II contrast_NN ,_, one_MC carrier_NN mother_NN seroconverted_VVD to_II anti-HBe_NN during_II pregnancy_NN and_CC the_DD antibody_NN persisted_VVD thereafter_RR ._.
P02656911A01
Hepatitis_NN B_NN virus_NN (_( HBV_NN )_) markers_NNS were_VBD determined_VVN in_II 821_MC patients_NNS receiving_VVG renal_JJ allografts_NNS and_CC undergoing_VVG immunosuppressive_JJ therapy_NN during_II 1970-1986_MC ._.
P02717151A06
HBeAg_NN carriers_NNS were_VBD twice_RR as_RR likely_RR to_TO be_VBI identified_VVN by_II their_PNG histories_NNS than_CSN HBsAg_NN carriers_NNS ._.
P02754427A02
Pre-S1_NN ,_, pre-S2_NN ,_, HBV_NN DNA_NN ,_, IgM_NN antihepatitis_NN core_NN antigen_NN (_( HBc_NN )_) ,_, hepatitis_NN B_NN e_NN antigen_NN (_( HBeAg_NN )_) ,_, and_CC anti-HBe_NN were_VBD detected_VVN in_II about_RR 200_MC sera_NNS serially_RR collected_VVN at_II different_JJ times_NNS for_II at_RR+ least_RR 6-12_MC months_NNS from_II the_DD onset_NN of_II clinical_JJ observation_NN ._.
P02764519A07
No_DD significant_JJ difference_NN in_II the_DD concordance_NN of_II HBV_NN infection_NN was_VBD observed_VVN in_II the_DD MZ_NN and_CC DZ_NN twins_NNS ._.
P02788545A04
Patients_NNS with_II chronic_JJ type_NN B_NN hepatitis_NN also_RR had_VHD significantly_RR higher_JJR levels_NNS of_II soluble_JJ Tac_NN peptide_NN than_CSN normal_JJ controls_NNS ,_, although_CS only_RR 63.6_MC %_SYM (_( 21_MC /_SYM 33_MC )_) of_II them_PN had_VHD a_DD level_NN greater_JJR than_CSN the_DD upper_JJ limit_NN of_II normal_NN ._.
P02800564A11
Virus_NN particles_NNS which_PNR were_VBD indistinguishable_JJ from_II Dane_NN particles_NNS were_VBD seen_VVN in_II the_DD cytoplasmic_JJ vacuoles_NNS of_II the_DD cultured_VVNJ cells_NNS by_II electron_NN microscopy_NN ._.
P02820093A12
HBVDNA_NN concentration_NN was_VBD not_RR diagnostic_JJ of_II disease_NN activity_NN on_II liver_NN biopsy_NN ._.
P02849883A02
Their_PNG prevalences_NNS were_VBD compared_VVN to_II those_PND of_II a_DD control_NN group_NN of_II 124_MC age_NN and_CC sex_NN matched_VVNJ black_NN HBV_NN carriers_NNS without_II tumor_NN ._.
P02940332A06
The_DD results_NNS suggested_VVD that_CST in_II our_PNG children_NNS ,_, most_DD HBsAg_NN carriers_NNS resulted_VVD from_II infections_NNS before_II 3_MC years_NNS of_II age_NN ,_, and_CC HBV_NN infections_NNS after_II 3_MC years_NNS of_II age_NN infrequently_RR resulted_VVD in_II a_DD carrier_NN state_NN ._.
P02947972A02
However_RR ,_, no_DD correlation_NN was_VBD observed_VVN between_II intrauterine_JJ infection_NN of_II infants_NNS and_CC the_DD presence_NN of_II antibodies_NNS of_II immunoglobulin_NN M_NN (_( IgM_NN )_) class_NN antibodies_NNS against_II hepatitis_NN B_NN core_NN antigen_NN (_( anti-HBc_NN )_) in_II maternal_JJ blood_NN ,_, nor_CC was_VBD HBeAg_NN found_VVN in_II maternal_JJ or_CC cord_NN sera_NNS ._.
P03009704A01
Antibody_NN profiles_NNS for_II cytomegalovirus_NN (_( CMV_NN )_) ,_, hepatitis_NN A_NN virus_NN (_( HAV_NN )_) ,_, hepatitis_NN B_NN virus_NN (_( HBV_NN )_) and_CC the_DD delta-agent_NN were_VBD determined_VVN on_II 55_MC serum_NN samples_NNS drawn_VVN from_II 55_MC Saudi_NN patients_NNS on_II maintenance_NN haemodialysis_NN for_II periods_NNS ranging_VVG from_II 1.5_MC months_NNS to_II 2_MC years_NNS ._.
P03360397A05
Cytoplasmic_JJ hepatitis_NN B_NN core_NN antigen_NN (_( HBcAg_NN )_) expression_NN was_VBD found_VVN in_II 9_MC out_II+ of_II 13_MC patients_NNS (_( 69_MC %_SYM )_) during_II acute_JJ exacerbation_NN ._.
P03402900A01
The_DD genome_NN of_II hepatitis_NN B_NN virus_NN (_( HBV_NN )_) contains_VVZ a_DD fourth_JJ open_JJ reading_VVGJ frame_NN (_( ORF_NN )_) ,_, designated_VVN X-region_NN ._.
P03429833A03
Pre-S_NN peptides_NNS were_VBD detected_VVN in_II the_DD serum_NN of_II 11_MC patients_NNS ,_, 10_MC of_II whom_PNR were_VBD positive_JJ for_II serum_NN HBV-DNA_NN and/or_CC liver_NN hepatitis_NN B_NN core_NN antigen_NN ._.
P03537207A02
Serial_JJ samples_NNS from_II 70_MC acutely_RR infected_VVNJ patients_NNS demonstrated_VVD that_CST anti-HBcIgM_NN may_VM detect_VVB 10_MC %_SYM more_DD positives_NNS than_CSN HBsAg_NN within_II 4_MC months_NNS after_II the_DD onset_NN of_II clinical_JJ symptoms_NNS ,_, and_CC all_PND except_II two_MC were_VBD negative_JJ for_II anti-HBcIgM_NN after_II the_DD fourth_JJ month_NN ._.
P03540211A07
Immunofluorescence_NN study_NN revealed_VVD HBsAg_NN in_II 20-30_MC %_SYM of_II hepatocytes_NNS and_CC hepatitis_NN B_NN core_NN antigen_NN (_( HBcAg_NN )_) in_II 2-3_MC %_SYM of_II the_DD cultured_VVNJ human_NN hepatocytes_NNS four_MC days_NNS after_II inoculation_NN ._.
P03585286A03
The_DD mother-infant_NN pairs_NNS were_VBD followed-up_VVD every_DD 3_MC months_NNS for_II at_RR+ least_RR 9_MC months_NNS ._.
P03616486A06
It_PN is_VBZ concluded_VVN that_CST HDV_NN superinfection_NN plays_VVZ a_DD significant_JJ role_NN in_II Taiwan_NNP in_II HBeAg_NN negative_JJ chronic_JJ hepatitis_NN B_NN patients_NNS with_II clinical_JJ "_`` exacerbation_NN "_'' ._.
P03653136A05
During_II follow-up_NN ,_, seroconversion_NN from_II HBeAg_NN to_II anti-HBe_NN with_II subsequent_JJ remission_NN of_II liver_NN disease_NN occurred_VVD in_II 82_MC %_SYM of_II patients_NNS presenting_VVG with_II detectable_JJ levels_NNS of_II anti-HBc_NN ,_, including_VVG three_MC out_II+ of_II seven_MC cases_NNS with_II chronic_JJ persistent_JJ hepatitis_NN ,_, but_CC in_II none_MC of_II the_DD cases_NNS that_PNR were_VBD initially_RR negative_JJ (_( P_NN less_RR than_CSN 0.01_MC )_) ._.
P03668273A04
None_MC of_II 9_MC HBsAg_NN positive_JJ pregnant_JJ women_NNS were_VBD carriers_NNS of_II HBeAg_NN ._.
P03669127A06
This_PND could_VM indicate_VVB an_DD important_JJ nonparenteral_JJ transmission_NN of_II HBV_NN in_II schools_NNS ._.
P03701304A03
The_DD titers_NNS correlated_VVD well_RR with_II hepatitis_NN B_NN viral_JJ DNA_NN (_( HBV_NN DNA_NN )_) and_CC hepatitis_NN B_NN e_NN antigen_NN (_( HBeAg_NN )_) in_II the_DD serum_NN ._.
P03723115A03
Our_PNG study_NN shows_VVZ that_CST perinatal_JJ transmission_NN is_VBZ relatively_RR unimportant_JJ in_II Kenya_NNP and_CC that_CST this_PND may_VM be_VBB a_DD consequence_NN of_II the_DD low_JJ levels_NNS of_II circulating_VVGJ HBV-DNA_NN in_II the_DD maternal_JJ plasma_NN ._.
P03743555A03
The_DD method_NN 's_GE detection_NN limit_NN was_VBD 10_MC (_( 5_MC )_) genome_NN equivalents_NNS or_CC 0.3_MC pg_NN DNA_NN per_II ml_NN ._.
P03765952A06
In_II sera_NNS recently_RR cleared_VVN of_II IgM_NN anti-HBc_NN ,_, mean_NN SGPT_NN activity_NN was_VBD detected_VVN twofold_NN the_DD normal_JJ value_NN in_II CPH_NN and_CC threefold_NN in_II CAH_NN patients_NNS ._.
P03784781A01
IgM_NN antibody_NN to_II hepatitis_NN B_NN core_NN antigen_NN (_( IgM_NN anti-HBc_NN )_) may_VM indicate_VVB an_DD active_JJ immune_JJ response_NN to_II persistent_JJ infection_NN with_II hepatitis_NN B_NN virus_NN (_( HBV_NN )_) ._.
P03855403A01
The_DD correlation_NN between_II serum_NN and_CC hepatic_JJ markers_NNS of_II hepatitis_NN B_NN virus_NN (_( HBV_NN )_) has_VHZ been_VBN studied_VVN in_II 70_MC subjects_NNS with_II chronic_JJ active_JJ hepatitis_NN of_II whom_PNR 18_MC were_VBD HBsAg+_NN and_CC 52_MC were_VBD HBsAg-_NN ._.
P03944482A08
Six_MC (_( 86_MC %_SYM )_) of_II seven_MC recipients_NNS of_II HBV_NN DNA-negative_JJ blood_NN units_NNS developed_VVD HBV_NN infection_NN ._.
P03956945A01
We_PN compared_VVD the_DD clinical_JJ and_CC serologic_JJ features_NNS of_II 118_MC hepatitis_NN B_NN surface_NN antigen_NN carriers_NNS with_II hepatitis_NN B_NN e_NN antibody_NN (_( anti-HBe_NN )_) followed_VVN up_II for_II 3-10_MC yr_NN (_( mean_NN 6.1_MC yr_NN )_) ,_, separated_VVN according_II+ to_II the_DD presence_NN or_CC absence_NN of_II hepatitis_NN B_NN virus-deoxyribonucleic_JJ acid_NN (_( HBV-DNA_NN )_) in_II serum_NN ._.
P03968544A01
Sera_NNS from_II four_MC groups_NNS of_II patients_NNS wtih_II different_JJ serologic_JJ markers_NNS of_II HBV_NN infection_NN were_VBD examined_VVN for_II HBV_NN DNA_NN using_VVG molecular_JJ hybridization_NN technique_NN and_CC for_II IgM_NN class_NN anti-HBc_NN using_VVG an_DD ELISA_NN based_VVN on_II the_DD antibody_NN capture_NN principle_NN ._.
P04035199A09
The_DD chi_NN 2_MC test_NN showed_VVD a_DD non_JJ significant_JJ difference_NN for_II frequencies_NNS of_II HBsAg_NN ,_, anti-HBc_NN alone_JJ ,_, anti-HBs_NNS but_CC a_DD significant_JJ one_PN for_II frequencies_NNS of_II no_DD HBV_NN markers_NNS in_II men_NNS and_CC women_NNS ._.
P04076727A02
Controls_NNS consisted_VVD of_II 90_MC patients_NNS without_II liver_NN disease_NN ._.
P06085625A01
Serum_NN samples_NNS were_VBD collected_VVN at_II the_DD time_NN of_II hospitalization_NN from_II 221_MC black_NN Africans_NNS suffering_VVG from_II cirrhosis_NN and_CC 453_MC suffering_VVG from_II hepatocellular_JJ carcinoma_NN (_( HCC_NN )_) ._.
P06100353A07
These_DD findings_NNS do_VDB not_RR support_VVB the_DD report_NN by_II Chung_NNP et_CC al._NN (_( 1983_MC ,_, J._NN Med._NN Virol._NN 11_MC :_: 99-104_MC )_) that_CST a_DD prolonged_VVNJ replicative_JJ phase_NN of_II chronic_JJ HBV_NN infection_NN is_VBZ essential_JJ for_II the_DD occurrence_NN of_II HCC_NN ._.
P06127059A02
An_DD increased_VVNJ prevalence_NN of_II anti-HBs_NNS was_VBD found_VVN in_II patients_NNS with_II systemic_JJ lupus_NN erythematosus_NN ._.
P06162990A02
Serum_NN samples_NNS from_II 102_MC PHC_NN patients_NNS and_CC from_II 100_MC control_NN individuals_NNS were_VBD tested_VVN for_II hepatitis_NN B_NN surface_NN antigen_NN (_( HBsAg_NN )_) ,_, antibody_NN to_II HBsAg_NN (_( anti-HBs_NNS )_) ,_, antibody_NN to_II hepatitis_NN B_NN core_NN antigen_NN (_( anti-HBc_NN )_) ,_, hepatitis_NN Be_NN antigen_NN (_( HBeAg_NN )_) ,_, and_CC antibody_NN to_II HBeAg_NN (_( anti-HBe_NN )_) ._.
P06188801A01
Serological_JJ evidence_NN of_II hepatitis_NN B_NN virus_NN (_( HBV_NN )_) infection_NN and_CC serum_NN alphafetoprotein_NN (_( AFP_NN )_) were_VBD assayed_VVN in_II sera_NNS from_II 112_MC Korean_JJ patients_NNS with_II primary_JJ hepatocellular_JJ carcinoma_NN (_( PHC_NN )_) and_CC from_II 63_MC age-_NN and_CC sex-matched_VVNJ controls_NNS ._.
P06204916A05
Although_CS HBsAg_NN was_VBD found_VVN in_II a_DD larger_JJR percentage_NN of_II PHC_NN patients_NNS (_( 81_MC %_SYM )_) ,_, it_PN was_VBD also_RR present_JJ in_II more_DD control_NN patients_NNS (_( 14_MC %_SYM )_) ._.
P06260695A06
Sera_NNS positive_JJ for_II any_DD HBV_NN marker_NN were_VBD also_RR tested_VVN for_II e_NN antigen_NN (_( HBeAg_NN )_) and_CC its_PNG antibody_NN (_( anti-HBe_NN )_) ._.
P06294917A03
The_DD presence_NN of_II anti-HBc_NN alone_JJ seemed_VVN to_TO denote_VVI previous_JJ hepatitis_NN B_NN virus_NN infection_NN ._.
P06313507A06
However_RR ,_, the_DD ultimate_JJ mechanism_NN regulating_VVG this_DD difference_NN awaits_VVZ further_JJ study_NN ._.
P06341197A04
In_II acute_JJ self-limited_VVNJ hepatitis_NN B_NN ,_, anti-HBc_NN IgM_NN (_( RIA_NN and_CC ELISA_NN )_) was_VBD initially_RR positive_JJ in_II all_DD 35_MC patients_NNS ._.
P06406288A09
The_DD results_NNS from_II this_DD study_NN indicate_VVB that_CST testing_VVGN for_II anti-HBc_NN IgM_NN may_VM improve_VVB serodiagnostic_JJ accuracy_NN when_CS acute_JJ NANB_NN and_CC delta-agent_NN hepatitis_NN occur_VVB in_II previously_RR unrecognized_VVNJ HBsAg_NN carriers_NNS ._.
P06475930A04
All_DD serum_NN samples_NNS were_VBD assayed_VVN by_II radioimmunoassay_NN to_TO determine_VVI presence_NN of_II HBsAg_NN ,_, antibody_NN to_II HBsAg_NN (_( anti-HBs_NNS )_) ,_, hepatitis_NN B_NN e_NN antigen_NN (_( HBeAg_NN )_) ,_, antibody_NN to_II hepatitis_NN B_NN e_NN antigen_NN (_( anti-HBe_NN )_) and_CC antibody_NN to_II hepatitis_NN B_NN core_NN antigen_NN (_( anti-HBc_NN )_) ._.
P06618432A05
All_DD six_MC were_VBD negative_JJ for_II nuclear_JJ HBcAg_NN and_CC serum_NN HBV_NN DNA_NN ,_, but_CC three_MC showed_VVD HBV_NN DNA_NN which_PNR appeared_VVD to_TO be_VBI integrated_VVN into_II unique_JJ sites_NNS in_II host_NN liver_NN DNA_NN by_II hybridization_NN analysis_NN ._.
P06637981A02
Overall_RR ,_, hepatitis_NN B_NN surface_NN antigen_NN (_( HBsAg_NN )_) was_VBD found_VVN in_II 6.4_MC %_SYM of_II those_PND tested_VVN ._.
P06693067A03
The_DD findings_NNS were_VBD correlated_VVN with_II results_NNS of_II tissue_NN immunofluorescence_NN for_II HBV_NN antigens_NNS and_CC the_DD presence_NN of_II serum_NN hepatitis_NN B_NN e_NN antigen_NN (_( HBeAg_NN )_) ,_, together_RR with_II histologic_JJ assessment_NN of_II each_DD liver_NN ._.
P07111979A11
We_PN correlate_VVB the_DD presence_NN of_II HBsAg_NN --_: regardless_II+ of_II the_DD level_NN of_II titer_NN of_II it_PN --_: with_II high_JJ titers_NNS of_II anti-HBc_NN and_CC the_DD presence_NN of_II anti-HBs_NNS with_II low_JJ titers_NNS (_( P_NN less_RR than_CSN less_RR than_CSN 0,0001_MC )_) ._.
P07229619A05
The_DD three_MC serologic_JJ parameters_NNS ,_, anti-HBc_NN ,_, anti-DNA_NN ,_, and_CC e-antigen_NN /_SYM antibody_NN ,_, should_VM together_RR prove_VVB useful_JJ for_II the_DD evaluation_NN of_II the_DD clinical_JJ status_NN of_II chronic_JJ HBsAg_NN carriers_NNS ._.
P07229621A01
A_DD new_JJ commercially_RR available_JJ radioimmunoassay_NN (_( RIA_NN )_) (_( Abbott-HBeTM_NN )_) was_VBD used_VVN for_II determination_NN of_II hepatitis_NN B_NN e-antigen_NN (_( HBeAg_NN )_) and_CC its_PNG antibody_NN (_( anti-HBe_NN )_) ._.
P07229621A14
The_DD usefulness_NN of_II HBeAg_NN /_SYM anti-HBe_NN in_II the_DD evaluation_NN of_II infectivity_NN and_CC prognosis_NN in_II hepatitis_NN B_NN has_VHZ been_VBN limited_VVN by_II the_DD low_JJ sensitivity_NN of_II the_DD earlier_JJR test_NN systems_NNS ._.
P07229626A03
In_II six_MC chimpanzees_NNS in_II which_PNR HGsAg_NN was_VBD detected_VVN for_II 16_MC weeks_NNS or_CC longer_RR ,_, HBeAg_NN was_VBD detected_VVN early_RR in_II the_DD infection_NN ;_: in_II five_MC ,_, anti-HBe_NN became_VVD detectable_JJ and_CC HBeAg_NN undetectable_JJ prior_II+ to_II the_DD clearance_NN of_II HBsAg_NN ._.
P07241093A03
The_DD significance_NN of_II relationship_NN between_II the_DD titer_NN of_II HBsAg_NN ,_, HBeAg_NN ,_, anti-HBe_NN ,_, and_CC anti-HBc_NN were_VBD statistically_RR analyzed_VVN ._.
P07348762A05
Among_II 15_MC patients_NNS with_II persistent_JJ HBsAg_NN ,_, anti-HBc_NN IgM_NN was_VBD present_JJ from_II 7_MC months_NNS to_II more_RR than_CSN 8_MC years_NNS ._.
P07508491A05
Two_MC sera_NNS from_II the_DD cases_NNS of_II acute_JJ HB_NN showed_VVD strong_JJ reactivity_NN of_II the_DD IgG3_NN isotype_NN with_II HBc_NN /_SYM eAg_NN peptides_NNS 61-85_MC ._.
P07787166A03
The_DD remaining_VVGJ 51_MC subjects_NNS (_( 58.0_MC %_SYM )_) were_VBD positive_JJ for_II anti-HBc_NN alone_JJ ;_: 50_MC of_II them_PN received_VVD a_DD four-dose_NN schedule_NN of_II hepatitis_NN B_NN (_( HB_NN )_) vaccine_NN ._.
P07897364A06
Following_VVG 1_MC month_NN of_II treatment_NN with_II interferon-alpha_NN 2b3_NN miu_NN three_MC times_NNS weekly_RR ,_, alanine_NN aminotransferases_NNS returned_VVD to_II normal_JJ levels_NNS while_CS cryoglobulins_NNS and_CC immune_JJ complexes_NNS disappeared_VVD from_II serum_NN ._.
P08294088A01
Serum_NN IgM_NN anti-HBc_NN was_VBD determined_VVN in_II 135_MC chronic_JJ HBsAg_NN carriers_NNS with_II various_JJ categories_NNS of_II histological_JJ activity_NN on_II liver_NN biopsy_NN and_CC hepatitis_NN B_NN serological_JJ profile_NN ._.
P08405860A02
The_DD aim_NN of_II this_DD study_NN was_VBD to_TO perform_VVI detailed_VVNJ serological_JJ and_CC biochemical_JJ analysis_NN during_II periods_NNS of_II active_JJ liver_NN disease_NN to_TO better_RRR understand_VVI the_DD mechanisms_NNS responsible_JJ for_II the_DD cyclic_JJ nature_NN of_II liver_NN injury_NN ._.
P08440421A07
The_DD serological_JJ profile_NN of_II HBsAg-positive_JJ /_SYM low_JJ or_CC negative_JJ anti-HBc_NN titer_NN and_CC increased_VVNJ anti-HBc_NN titer_NN with_II abnormal_JJ serum_NN ALT_NN levels_NNS are_VBB not_RR necessarily_RR exceptional_JJ in_II HBeAg-positive_JJ adolescent_NN ASC_NN ._.
P08488126A08
More_DD studies_NNS showed_VVD the_DD trans-activating_VVGJ properties_NNS of_II HBxAg_NN ;_: actually_RR the_DD X_NN protein_NN seems_VVZ to_TO be_VBI involved_VVN in_II replicative_JJ cycle_NN of_II HBV_NN ._.
P08520247A04
The_DD donor_NN follow-up_NN times_NNS ranged_VVD from_II 1.2_MC to_II 13.5_MC years_NNS ._.
P08685787A02
DESIGN_NN :_: A_DD sero-epidemiological_JJ community-based_VVNJ cross-sectional_JJ study_NN ._.
P08685787A14
However_RR ,_, standardisation_NN for_II year_NN of_II data_NNS collection_NN and_CC province_NN resulted_VVD in_II a_DD relative_JJ risk_NN of_II 2.0_MC ,_, i.e._CC the_DD risk_NN of_II being_VVGN HBsAg-positive_JJ in_II rural_JJ areas_NNS is_VBZ twice_RR as_RR high_JJ as_CSN in_II urban_JJ areas_NNS ._.
P08707245A05
Tupaias_NNS can_VM also_RR be_VBB infected_VVN with_II HBV_NN in_RR+ vivo_RR ,_, resulting_VVG in_II viral_JJ DNA_NN replication_NN and_CC gene_NN expression_NN in_II tupaia_NN livers_NNS ._.
P08835741A04
Ten_MC infants_NNS became_VVD HBsAg_NN carriers_NNS ,_, and_CC their_PNG mothers_NNS had_VHD significantly_RR lower_JJR anti-HBc_NN titers_NNS than_CSN those_PND of_II the_DD mothers_NNS of_II 182_MC infants_NNS who_PNR did_VDD not_RR become_VVB carriers_NNS (_( p_NN =_SYM 0.003_MC )_) ,_, while_CS maternal_JJ serum_NN hepatitis_NN B_NN virus_NN DNA_NN levels_NNS (_( 29.9_MC +/-_SYM 23.6_MC versus_CC 39.9_MC +/-_SYM 58.1_MC pg_NN /_SYM 10_MC ml_NN )_) did_VDD not_RR differ_VVB in_II those_DD two_MC groups_NNS (_( p_NN >_SYM 0.25_MC )_) ._.
P08931411A06
IgM_NN anti-HBc_NN and_CC HBeAg_NN levels_NNS were_VBD compared_VVN to_II initial_JJ serum_NN HBV_NN DNA_NN ,_, DNA_NN polymerase_NN ,_, serum_NN aminotransferase_NN levels_NNS ,_, and_CC demographic_JJ features_NNS ._.
P09139082A04
The_DD former_JJ group_NN of_II carrier_NN is_VBZ considered_VVN to_TO be_VBI at_II a_DD higher_JJR risk_NN of_II transmitting_VVGN HBV_NN infection_NN than_CSN the_DD latter_NN ._.
P09185774A04
The_DD median_JJ follow-up_NN period_NN was_VBD 20_MC months_NNS (_( range_NN ,_, 2-59_MC months_NNS )_) ._.
P09398007A07
Serum_NN ALT_NN remained_VVD persistently_RR normal_JJ and_CC HBV_NN DNA_NN undetectable_JJ by_II dot-blot_NN assay_NN in_II 6_MC initial_JJ responders_NNS and_CC 1_MC initial_JJ nonresponder_NN ,_, compared_VVN with_II none_MC of_II the_DD 21_MC untreated_VVNJ controls_NNS (_( sustained_VVNJ response_NN :_: 33_MC %_SYM vs._CC 0_MC ;_: P_NN <_SYM .001_MC )_) ._.
P09407340A11
The_DD mechanism_NN of_II intrahepatic_JJ shift_NN of_II HBcAg_NN from_II the_DD nucleus_NN to_II the_DD cytoplasm_NN and_CC the_DD decreased_VVNJ levels_NNS of_II viraemia_NN in_II this_DD phase_NN may_VM be_VBB ,_, at_RR+ least_RR in_II part_NN ,_, secondary_JJ to_II liver_NN damage_NN and_CC regeneration_NN ._.
P09425944A12
In_II contrast_NN ,_, HBeAg-containing_VVGJ immune_JJ complexes_NNS were_VBD still_RR detected_VVN after_II SC_NN ._.
P09493518A04
They_PN were_VBD followed-up_VVN bimonthly_RR with_II routine_JJ liver_NN function_NN tests_NNS ,_, and_CC HBcAb_NN IgM_NN titres_NNS were_VBD also_RR determined_VVN ._.
P09506393A04
After_II selecting_VVGN HEPAXPERT_NN /_SYM WWW_NN ,_, serologic_JJ test_NN results_NNS can_VM be_VBB entered_VVN and_CC will_VM be_VBB transferred_VVN as_II an_DD e-mail_NN message_NN for_II subsequent_JJ interpretation_NN which_PNR is_VBZ done_VDN off-line_NN with_II HEPAXPERT-III_NN ._.
P09715416A01
Approximately_RR 15_MC %_SYM of_II Indian_JJ patients_NNS with_II hepatitis_NN B_NN virus_NN (_( HBV_NN )_) -related_VVNJ chronic_JJ liver_NN disease_NN (_( CLD_NN )_) have_VHB infection_NN with_II precore_NN mutant_NN forms_NNS ._.
P09715416A14
This_DD study_NN concluded_VVD that_CST :_: 1_MC ._.
P09738719A10
CONCLUSIONS_NNS :_: Current_JJ immunoprophylaxis_NN strategy_NN does_VDZ not_RR protect_VVB newborns_NNS with_II surface_NN antigenemia_NN ,_, apparently_RR acquired_VVN in_II utero_NN ,_, from_II becoming_VVGN HBV_NN carriers_NNS ._.
P10607224A03
The_DD proportion_NN of_II infected_VVNJ people_NNS who_PNR become_VVB chronic_JJ carriers_NNS ranges_VVZ from_II about_RR 80_MC to_II 95_MC %_SYM for_II babies_NNS born_VVN to_II HBsAg_NN /_SYM HBeAg-positive_JJ mothers_NNS ._.
P10960459A07
Of_II the_DD 77_MC samples_NNS with_II detectable_JJ HBV-DNA_NN titers_NNS below_II 3.75_MC x_SYM 10_MC (_( 5_MC )_) copies_NNS by_II TaqMan_NN ,_, only_RR 13_MC were_VBD detected_VVN by_II bDNA_NN ._.
P11555188A12
Several_JJ other_JJ antiviral_JJ agents_NNS are_VBB currently_RR being_VBG evaluated_VVN in_II this_DD setting_VVGN with_II combined_VVNJ regimens_NNS being_VVGN the_DD most_RRT reasonable_JJ step_NN for_II the_DD near_JJ future_NN ._.
P11703579A07
In_II addition_NN ,_, we_PN analysed_VVD serum_NN samples_NNS from_II 8_MC anti-HBe-positive_JJ patients_NNS who_PNR had_VHD been_VBN receiving_VVG lamivudine_NN treatment_NN for_II more_RR than_CSN three_MC years_NNS ._.
P12239179A04
The_DD 95_MC %_SYM detection_NN limit_NN of_II the_DD method_NN amounted_VVD to_II 27.8_MC IU_NN /_SYM mL_NN ,_, consistent_JJ with_II the_DD World_NN Health_NN Organization_NN (_( WHO_NN )_) international_JJ standard_NN for_II HBV_NN DNA_NN ._.
P12421455A12
Under_II certain_JJ conditions_NNS ,_, kidneys_NNS from_II HBV-infected_VVNJ donors_NNS can_VM be_VBB safely_RR used_VVN and_CC thus_RR prevent_VVB unnecessary_JJ discarding_VVGN of_II organs_NNS ._.